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Abstract
Four different human breast cancer cell lines were examined to search for genes associated with tumor growth and
metastasis. Each of these cell lines, MDA-MB-453, MCF-7, MDA-MB-231 and MDA-MB-435, displays different
phenotypic characteristics ranging from poorly to highly tumorigenic and metastatic. The differences in gene expression
profiles of these cell lines generated by differential display technique should allow one to identify candidates as putative
oncogenes or tumor/metastasis suppressor genes. A novel cDNA expressed in the highly tumorigenic and metastatic cell line,
MDA-MB-435, was identified and isolated by this approach. The function for this gene, designated ALP56 (aspartic-like
protease 56 kDa), in tumor progression is suggested by the homology of the encoded protein to aspartic proteases, such as
cathepsin D. The amino acid residues in two catalytic domains of this family are highly conserved in those domains of
ALP56. Northern hybridization indicated that the expression of ALP56 is associated with growth and metastasis of MDA-
MB-435 tumors in immunodeficient mice. In situ hybridization of biopsies from breast cancer and colon cancer patients
indicated that ALP56 is upregulated in human primary tumors and liver metastasis. These results suggest that this novel gene
correlates with human tumor progression. ß 2000 Elsevier Science B.V. All rights reserved.
Keywords: Aspartic protease; Metastasis ; Breast cancer; Colon cancer; Di¡erential display
1. Introduction
Metastasis, the spread of malignant tumor cells
from a primary site to distant sites, is a highly selec-
tive process involving multiple host^tumor interac-
tions [1^5]. Some of these interactions are common
to all cancers, such as the escape from the host im-
mune surveillance and the onset of angiogenesis,
whereas other interactions are cancer-type speci¢c
and in£uenced by the organ environment [6,7]. For
example, breast cancer metastases are predominantly
found in lung and bone [8,9]. These observations
have led to the conclusion that metastasis is not a
random process, but rather a precise series of molec-
ular events involving the coordinate expression of
speci¢c sets of genes [10^12]. Identi¢cation of these
genes and their functions should have strong impli-
cations for diagnosis and treatment of metastatic
cancer.
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Primary tumor properties, such as histological
grading and expression of genes for hormone recep-
tors, growth factor receptors and tumor suppressors
have been described as potential prognostic markers
to identify patients with a high probability of devel-
oping metastasis [13^15]. For example, estrogen re-
ceptor-positive breast cancer patients have a better
prognosis and are more likely to respond to hormone
therapy than patients lacking estrogen receptor ex-
pression [16]. In addition, much work on staging
tumor progression has focused on proteolytic en-
zymes. The release of matrix-degrading enzymes,
such as collagenase and cathepsin D, is thought to
play a vital role for tumor cell invasiveness [17,18].
Consistent with this view, proteases have been found
at the advancing front of invasive tumors overex-
pressed by either the breast cancer cells themselves
or by the surrounding stroma tissue of the host
[3,18^20]. Accordingly, several clinical studies have
shown that a high level of protease activity in breast
tumors is an indicator for poor disease outcome
[21^24].
Several approaches have been taken to identify
and compare gene expression in normal and disease
states [25^30]. The di¡erential display technique was
chosen in this study based on its ability to identify
both upregulated genes (putative oncogenes) and
downregulated genes (putative tumor/metastasis sup-
pressor genes) simultaneously. Di¡erential display
(DD) is a powerful technique to compare patterns
of gene expression in RNA samples of di¡erent types
or under di¡erent biological conditions [27,28]. The
technique produces partial cDNA fragments by a
combination of reverse transcription (RT) and PCR
of randomly primed RNA. Changes in the expression
level of genes are identi¢ed after separation of the
cDNAs on sequencing-type gel. As a ¢rst step, the
gene expression pro¢les of di¡erent human breast
cancer cell lines with widely divergent malignant phe-
notypes were compared. Human breast cancer cell
lines were chosen as start material based on the fea-
sibility to obtain large amounts of pure RNA. In
contrast, human breast cancer biopsies consist of a
mixture of cancer and other cell types including mac-
rophages and lymphocytes [31,32], which leads to the
detection of false positive possibilities. Moreover, the
human breast cancer cell lines described in this study
have been extensively studied in mouse models allow-
ing one to functionally characterize the role of can-
didate genes in tumor progression using animal mod-
els. Our hypothesis is that the phenotypic di¡erences
of cell lines are based on genetic changes that man-
ifest themselves in the expression of speci¢c mRNA
transcripts.
2. Materials and methods
2.1. Cell lines
Human breast cancer cell lines MCF-7, ZR-75-1,
MDA-MB-231, MDA-MB-361, MDA-MB-435,
MDA-MB-453, MDA-MB-468, Alab and a non-tu-
morigenic myo-epithelial breast cell line from normal
breast tissue, Hs578Bst, were cultured in DMEM
(Biowhittaker, Walkersville, MD) supplemented
with 10% fetal calf serum, 10 mM sodium pyruvate
(Biowhittaker, Walkersville, MD), 1 mM non-essen-
tial amino acids (Gibco-BRL, Grand Island, NY),
20 mM sodium glutamine (Sigma, St. Louis, MO),
and 1UMEM vitamin solution (Gibco-BRL, Grand
Island, NY). COS-7 cells were cultured in DMEM
supplemented with 10% fetal calf serum and 10 mM
sodium glutamine.
2.2. Di¡erential display
Di¡erential display was performed using the Hier-
oglyph mRNA pro¢le kit according to the manufac-
turer’s conditions (Genomyx, Foster City, CA). A
total of 200 primer pairs were used to pro¢le gene
expression. Following ampli¢cation of randomly
primed mRNAs by reverse-transcription-polymerase
chain reaction (RT-PCR) the cDNA products were
separated on 6% sequencing gels using a genomyxLR
sequencer (Genomyx). The dried gels were exposed
to Kodak XAR-2 ¢lm (Kodak, Rochester, NY) for
various times. Di¡erentially expressed cDNA frag-
ments were excised and reampli¢ed according to
the manufacturer’s conditions (Genomyx). Because
a slice excised from the gel could contain 1^3
cDNA fragments of the same size [33,34], reampli¢ed
PCR products were separated by single strand con-
¢rmation polymorphism gels as described in [35] and
directly sequenced using M13 universal and T7 prim-
ers.
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2.3. Construction and screening of human bone
marrow stroma cell cDNA library and
site-directed mutagenesis
RNA was isolated from human bone marrow stro-
ma cells (Poietic Technologies, Germantown, MD)
by guanidinium thiocyanate/phenol chloroform ex-
traction protocol [36]. Poly(A) RNA was isolated
using oligo-dT spin columns (Stratagene, La Jolla,
CA). First and second strand synthesis were per-
formed according to the manufacturer’s conditions
(Pharmacia, Piscataway, NJ). Double-stranded
cDNA was ligated into pBK-CMV phagemid vector
(Stratagene, La Jolla, CA). Approximately, 1U106
plaques were screened using a probe of 1.2-kb
cDNA fragment from di¡erential display. Plasmid
DNA from positive clones was obtained according
to the manufacturer’s conditions. The correctness
of the nucleotide sequence was determined by dou-
ble-strand sequencing.
Oligonucleotide-directed construction of mutations
within the catalytic domains of ALP56 (amino acids
110 and 303) was performed using the following
primers: 5P-GCAGAAGCTACAGATTCTCGTCG-
CGACTGGAAG-3P for amino acid position 110 in-
troducing a NruI restriction enzyme site and 5P-
GCAGACAAGGCCATCGTGGCTAGCGGCAC-
CACGCTGCTGC-3P for amino acid position 303
introducing a NheI restriction enzyme site. Only the
sense strand is shown with the restriction enzyme
sites underlined and changed nucleotides in italics.
Mutations were introduced using the Quickchange
Mutagenesis kit (Stratagene, La Jolla, CA) according
to the manufacturer’s conditions.
2.4. Northern blot analysis and in situ hybridization
Northern Tissue blots were purchased from Clon-
Tech (Palo Alto, CA), which contain poly(A) RNA
prepared from various human normal tissues. Other
Northern blots were prepared using 20^30 Wg total
RNA from eight human breast cancer cell lines and a
normal breast cell line, or from seven kinds of pri-
mary tumors produced by severe combined immuno-
de¢cient mice (SCID) injected with di¡erent human
breast cancer cell lines, or from lung metastatic foci
of MDA-MB-435 injected mice. Northern blots were
hybridized at 65‡C in Express-hyb solution (Clon-
Tech) with radiolabeled probes.
In situ hybridization was performed on human
tissues frozen immediately after surgical removal
and cryosectioned at 10 Wm, following the protocol
of Pfa¡ et al. [37]. The digoxigenin-UTP labeled ri-
boprobes were generated with a template plasmid
containing ALP56 cDNA. For the generation of
the antisense probe, the DNA was linearized at the
5P-end and transcribed with T3 polymerase to gener-
ate a transcript of approximately 1 kb in length. For
the sense control, the DNA was linearized at the 3P-
end and transcribed with T7 polymerase. Hybridized
probes were detected with alkaline phosphatase-
coupled anti-digoxigenin antibodies using BM Purple
as the substrate (Roche Molecular Biochemicals, In-
dianapolis, IN).
2.5. Tumor growth in the mammary fat pad of
immunode¢cient mice and analysis of lung
metastasis
Five-week-old severe combined immunode¢cient
C.B.-17 mice (Charles River, Boston, ME) were anes-
thetized and a small incision was made to expose the
mammary fat pad [38]. Approximately 2.5U106 hu-
man breast cancer cells of MCF-7, ZR-75-1, MDA-
MB-231, MDA-MB-361, MDA-MB-435, MDA-MB-
453, MDA-MB-468 and Alab were injected into the
mammary fat pad, respectively, and the wound was
clipped. Mice injected with MCF-7 cells received a
pellet of 17L-estradiol subcutaneously 1 week before
tumor cell injection (0.36 mg over a releasing period
of 60 day, Innovative Res. of America, Sarasota, FL)
[39]. Other estrogen receptor (ER)-positive cell lines,
ZR-75-1 and MDA-MB-361, did not require exoge-
nous estradiol for tumor growth [40]. Tumor growth
was monitored by weekly examinations and caliper
measurements.
In the case of MDA-MB-231, MDA-MB-435 and
Alab, primary tumors were surgically removed from
mice 5^6 weeks after tumor cell injection, when tu-
mor volume reached 600^1000 mm3. In the case of
MDA-MB-468, MCF-7, ZR-75-1 and MDA-MB-
361, primary tumors were removed about 60 days
after tumor cell injection, when tumor volumes
reached 60^100 mm3. To examine the metastatic
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potential of human breast cancer cell, mice were
killed on day 42 after primary tumor removal. Lungs
were inspected for the presence of metastatic foci
under the microscope and by hematoxylin and eosin
staining after lungs embedded into OCT gel (Sakura
Finetek, Torrance, CA).
2.6. Expression of ALP56 in COS cells and in a
cell-free protein synthesis system
Transient transfections of ALP56 DNA into COS-
7 cells were performed as described in [41] using
DEAE-dextran/chloroquine procedure. Expression
of ALP56 in a cell-free protein synthesis system
was performed according to the manufacturer’s con-
ditions (Promega, Madison, WI). Protein protection
experiments in the presence of dog pancreatic micro-
somes (Promega) were done on ice for 30 min as
speci¢ed in the ¢gure legends. Radiolabeled proteins
were analyzed by SDS-PAGE and visualized by
autoradiography.
3. Results
3.1. Identi¢cation of a gene di¡erentially expressed in
the highly tumorigenic and metastatic human
breast cancer cell line, MDA-MB-435
To identify genes associated with the progression
of breast cancer to the metastatic state, the gene ex-
pression pro¢les of four human breast cancer cell
lines were compared. The cell lines display di¡erent
malignant phenotypes ranging from poorly to highly
Fig. 1. Arbitrary primer based di¡erential display and con¢rmation by RNA blot analysis of di¡erent human breast cancer cell lines.
(A) Autoradiograph of a di¡erential display gel depicting two bands of approximately 1.2-kb in size from human breast cancer cell
line, MDA-MB-435. Di¡erential display reactions were prepared and run in duplicate. (B) Northern blot analysis validating the ex-
pression pattern in highly tumorigenic human breast cancer cell lines. The cDNAs isolated from the di¡erential display gel hybridized
to two transcripts of approximately 2.0 and 2.5 kb in size. Equal amounts of RNA in each lane were loaded as judged by hybridiza-
tion of the membrane with a human L-actin probe.
C
Fig. 2. Nucleotide sequence and deduced amino acid sequence of ALP56. (A) The 518 amino acid long sequence is shown in single
letter code below the nucleotide sequence consisting of 1855 base pairs. The active site D residues and £anking amino acid residues
characteristic of aspartic proteases, putative N-terminal signal peptide and C-terminal transmembrane domain are underlined. The pu-
tative propeptide is boxed. (B) Expressed sequence tags extending the nucleotide sequence to 2606 base pairs in length. (C) Schematic
representation of ALP56. SS, signal sequence; Pro, propeptide; TM, transmembrane domain. The asterisks indicate the active sites.
Bold residues, D (amino acids 110 and 303) in catalytic domains are changed to alanine in the site-directed mutant.
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tumorigenic and metastatic in the following order,
MDA-MB-453, MCF-7, MDA-MB-231 and MDA-
MB-435 [38,42^44]. MCF-7 is estrogen receptor-pos-
itive line and MDA cell lines are estrogen receptor
negative. Therefore, the study should also identify
genes that are under estrogen receptor regulation.
To ensure that these cell lines had retained originally
described phenotypic properties after prolonged pas-
sage in culture, their potential to establish primary
tumors in the mammary fat pad of SCID mice and
to develop lung metastasis was examined. Consistent
with previous reports [38,42^44], MCF-7, MDA-
MB-231, and MDA-MB-435 formed primary tumors
and no primary tumor formation was detected with
MDA-MB-453 (data not shown). Accordingly, mice
injected with MDA-MB-231 and MDA-MB-435 de-
veloped lung metastasis (data not shown).
A di¡erential display analysis using total RNA
isolated from four human breast cancer cell lines
was performed with a total of 200 primer pair com-
binations as described in the Section 2. Among sev-
eral di¡erentially expressed transcripts, two cDNA
fragments of approximately 1.2 kb in size were spe-
ci¢cally ampli¢ed from the MDA-MB-435 RNA
sample using the primer pair combination, Ap8 (5P-
ACGACTCACTATAGGGC(T)12AA) and Ap1 (5P-
ACAATTTCACACAGGACGACTCCAAG) (Fig.
1A, lanes 5 and 6). Similar sized cDNA fragments,
although with much weaker intensity, were also de-
tected in MDA-MB-231 (lanes 1 and 2). No signal
using this primer pair was monitored in the RNA
samples isolated from the poorly metastatic MCF-7
and the non-tumorigenic MDA-MB-453 cell lines
(lanes 3 and 4, 7 and 8). Nucleotide sequence deter-
mination showed that the two cDNAs were identical.
To con¢rm the expression pattern of this cDNA in
the MDA-MB-435 cell line, Northern blot analysis
was performed. We included additional human
breast cancer lines and a normal breast cell line in
this experiment (Fig. 1B). The probe hybridized to
two transcripts of approximately 2.0 and 2.5 kb in
size. The strongest signals were detected in the tu-
morigenic line, MDA-MB-468 and in the highly
metastatic line, MDA-MB-435 (lanes 6 and 9).
Weak expression was monitored in the tumorigenic
line, ZR-75-1 and the metastatic lines, MDA-MB-
361, Alab and MDA-MB-231 (lanes 4, 5 and 7, 8).
No signal was detected in the tumorigenic, but
poorly metastatic cell line, MCF-7. Similarly, no sig-
nal was detected in the non-tumorigenic line, MDA-
MB-453, and in the normal breast cell line, Hs578Bst
(lanes 3, 2 and 1). The results from the Northern blot
analysis were consistent with the di¡erential display
results and correlated with the expression of this gene
in the tumorigenic human breast cancer cell lines.
To obtain more nucleotide sequence information,
a human bone marrow stroma cell cDNA library was
screened. One of the positive clones extended the al-
ready obtained sequence information at the 5P end to
1855 nucleotides in length (Fig. 2A). This sequence
was further extended at the 3P-end with several ex-
pressed sequenced tags to a ¢nal length of 2606 nu-
cleotides (Fig. 2B, GenBank accession number:
AF117892). The additional 750 nucleotides are
most probably the result of alternative poly(A) site
selection. Analysis of the nucleotide sequence re-
vealed a single open reading frame of 518 amino
acids, beginning with a start codon for translation
at nucleotide position 101 and terminating with a
stop codon at nucleotide position 1655. A consensus
Kozak sequence [45] around the start codon and the
analysis of codon usage (Wisconsin package, UNIX)
suggests that this cDNA clone contains the entire
coding region. On the basis of its homology to
known proteases (see below), the cDNA-encoded
protein was termed ALP56 for aspartic-like protease
56 kDa.
3.2. ALP56, a novel aspartic-like protease
Comparison of the ALP56 open reading frame
with proteins in databases showed homology to
members of the pepsin family of aspartic proteases
(Fig. 3). A characteristic feature of this protease fam-
ily is the presence of two active centers [52,53]. The
amino acid residues comprising the catalytic domains
(Asp-Thr/Ser-Gly) and the £anking residues display
the highest conservation in this family, which are
conserved in ALP56 (Fig. 3). Moreover, ALP56 con-
tains a putative signal sequence (amino acids 8^20)
and a stretch of approximately 57 amino acid resi-
dues representing a putative propeptide (amino acids
21^77). Overall similarity of ALP56 to pepsinogen C
and A, renin, napsin, cathepsin D and E are 55, 51,
54, 52, 52 and 51%, respectively. We therefore tenta-
tively conclude that this novel gene encodes an as-
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Fig. 3. Multiple amino acid sequence alignment of ALP56 with members of the pepsin family of aspartic proteases. Identical amino acid residues are indicated by
black boxes. A bar on top indicates the aspartic protease active residues (DTGS/DTGT). The putative transmembrane domain is underlined. Gaps are indicated by
dots. CatE, human cathepsin E [46]; PepA, monkey pepsinogen A [47]; PepC, human pepsinogen C [48]; CatD, human cathepsin D [49]; Renin, human [50]; Nap,
human Napsin-A [51].
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partic-like protease. Unlike the other members of the
aspartic protease family, ALP56 contains a long C-
terminal extension (Figs. 2C and 3). Computer aided
inspection of the C-terminal extension identi¢ed a
stretch of 29 hydrophobic amino acids that could
function as a transmembrane domain (Figs. 2C and
3). The di¡erences in the primary structure between
ALP56 and other aspartic proteases raise interesting
questions concerning location and function of this
protein in human cells.
3.3. Expression of ALP56 throughout breast cancer
growth and metastasis of MDA-MB-435
In the data presented so far, the expression pro¢le
for ALP56 is based on human breast cancer cells
cultured in vitro. Comparison of gene expression
pro¢les of cultured cells with those of tissues have
shown di¡erences, suggesting that cell lines do not
necessarily re£ect tumors in their natural environ-
ment [48,54]. Therefore, we used the SCID mouse
model to further examine ALP56 expression in hu-
man tumors which were propagated in mice. This
model has been shown to be suitable for evaluating
the function of genes implicated in the tumorigenicity
and metastasis of human breast cancer cells [55,56].
Eight di¡erent human breast cancer cell lines were
injected into the mammary fat pad of SCID mice.
Primary tumors and, if applicable, lung metastasis
were isolated. The expression of ALP56 was exam-
ined by Northern blot analysis (Fig. 4). Consistent
with expression data obtained using cell lines cul-
tured in vitro, ALP56 transcripts were detected in
primary tumors derived from the MDA-MB-468
and MDA-MB-435 cell lines (lanes 4 and 7). The
expression of ALP56 was also detected in lung meta-
static foci of mice injected with MDA-MB-435 (lane
8). No or weak ALP56 transcripts were detected in
RNA samples from primary tumors derived from
other human breast cancer cell lines. These data cor-
relate with the expression pattern detected using cells
cultured in vitro and rule out culture conditions as a
cause for ALP56 upregulation in the highly tumori-
genic and the metastatic human breast cancer cell
lines MDA-MB-468 and MDA-MB-435.
3.4. ALP56 gene expression detected in breast and
colon cancer patient samples
Expression of ALP56 was further examined at the
RNA level using breast cancer patient biopsies by in
situ hybridization (Fig. 5A^F). ALP56 was highly
expressed in the tumor cells, but not in the surround-
ing lymphocytes (Fig. 5E). No signal was detected
using the sense probe (Fig. 5C,F). A weak ALP56
signal was detected in the cells of the ducts of normal
breast tissue (Fig. 5B and data not shown). Although
the primary tumor of the second patient showed only
a few positive signals, ALP56 transcripts were
strongly detected in lymph node metastasis of that
patient (data not shown). To examine whether
ALP56 expression is restricted to breast cancer biop-
sies or also expressed in other tumors, we examined
tissue samples obtained from colon cancer (Fig. 5G^
M). No signal was detected in normal colon tissue
(Fig. 5H), whereas ALP56 transcripts were abundant
in both primary tumor and liver metastatic foci. No
expression was detected in the surrounding stroma
(Fig. 5K,M). A similar expression pattern in primary
tumor and liver metastases was observed from a sec-
ond colon cancer patient (data not shown). In situ
hybridization of tissues from two patients with pros-
Fig. 4. ALP56 expression in primary tumor and lung metastatic
foci isolated from SCID mice. Northern blot analysis using
RNA isolated from primary tumors (PT) and lung metastatic
foci (Met) of mice injected with di¡erent human breast cancer
cell lines. Equal amounts of RNA in each lane were loaded as
judged by hybridization of the membrane with a human L-actin
probe.
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Fig. 5. In situ hybridization analysis of ALP56 expression in human breast and colon tumors: adjacent or near-adjacent sections
(A^F) came from one breast cancer patient. (A^C) Normal breast tissue. (D^F) Primary breast tumor. Adjacent or near-adjacent sec-
tions (G^M) came from one colon cancer patient. (G,H) Normal colon tissue. (J,K) Primary colon tumor. (L,M) Liver metastasis.
A, D, G, J and L were stained with hematoxylin and eosin. B, E, H, K and M were hybridized with the ALP56 antisense probe.
C and F were hybridized with the ALP56 sense probe. d, lactiferous duct; f, fatty connective tissue; ly, lymphocytes; m, colon muco-
sa; met, metastatic tissue; PT, primary tumor; st, stroma; tc, tumor cells.
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tate cancer showed that ALP56 is expressed in the
ductal epithelium of both normal and malignant
prostate (see below and data not shown).
3.5. Expression pattern of ALP56 in normal human
tissues
To determine the tissue distribution of ALP56,
poly(A) RNA from various human tissues was ex-
amined by Northern blot analysis (Fig. 6). Two ma-
jor transcripts were detected, which are similar in size
to those detected in the breast cancer cell lines and
tumor tissues. Highest expression of ALP56 was de-
tected in RNA isolated from pancreas, prostate and
placenta. After overexposure signals were detected in
all tissues except in brain and peripheral blood lym-
phocytes (data not shown).
3.6. Functional expression of ALP56
To examine the translational potential of this gene,
we inserted the ALP56 cDNA into an expression
vector containing the cytomegalovirus enhancer/pro-
moter and the translation initiation region of the
thymidine kinase gene [57]. In addition, the cDNA
sequence was extended at the 3P end to include sequen-
ces encoding 16 amino acid residues of the hem-
agglutinin (HA1) epitope tag [58]. COS cells were
transiently transfected with the cDNA and whole cell
extracts analyzed for protein expression (Fig. 7A).
Immunoblot analysis using a monoclonal antibody
directed against the HA1 tag detected a protein
with the expected molecular mass of approximately
60-kDa (indicated by an arrow). In addition, the
antibody detected two polypeptides with molecular
masses of 17 and 14 kDa (asteriks). These two poly-
peptides were absent in a mutant ALP56 protein in
which both aspartic acid residues (amino acid posi-
tions 110 and 303) in the catalytic centers have been
changed to alanine (lane 2) suggesting that ALP56
undergoes autoproteolytic cleavage.
The functionality of the signal peptide and the
putative transmembrane domain was examined by
expressing ALP56 in a cell-free transcription and
translation system (Fig. 7B,C). In vitro transcrip-
tion/translation of the ALP56 cDNA generated a
polypeptide of 60 kDa (lane 1), which is similar in
size to the product detected in COS cells. Addition of
microsomes to the translation reaction resulted in the
appearance of slower migrating products, suggesting
Fig. 6. Expression of ALP56 in human tissues. RNA blot anal-
ysis depicting two ALP56 transcripts of 2.0 and 2.5 kb in size
in various human tissues. sk. muscle, skeletal muscle; sm. intes-
tine, small intestine; p.b. lymphocytes, peripheral blood lym-
phocytes. The blot was exposed to ¢lm for 24 h at 380‡C.
Fig. 7. Expression of ALP56 in COS cells and in a cell-free
protein synthesis system. (A) Immunoblot analysis of whole cell
extracts transiently transfected with wild-type (wt) ALP56
cDNA or a mutant (mt) form in which both aspartic acid resi-
dues in the active sites have been mutated to alanine (see Fig.
2). The arrow indicates the full-length protein. The asterisks in-
dicate putative autoproteolytic products of ALP56. (B) In vitro
transcription/translation of ALP56 cDNA in the presence or
absence of microsomes. One half of the translation products
was treated with protease K (1 mg/ml) (lanes 2, 4 and 5) and
0.4% Triton X-100 (lanes 2 and 5). Translation products were
separated on 12% SDS-PAGE. MS, microsomes; TX, Triton
X-100; PK, proteinase K. (C) One half of each transcription/
translation of ALP56 cDNA was used as a no treatment con-
trol.
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import into microsomes and post-translational mod-
i¢cations (lane 3). Further proof of import into mi-
crosomes was provided by addition of proteinase K
to the translation products. As shown in lane 4, the
translation product is protected in the presence of
intact microsomes. In contrast, addition of detergent
and proteinase K resulted in completed degradation
of the translation product (lane 5). The appearance
of a slightly faster migrating polypeptide in lane 4
after addition of proteinase K suggests removal of C-
terminal amino acids behind the transmembrane do-
main. These data suggest a functional signal se-
quence for import into the endoplasmatic reticulum
and the presence of a transmembrane domain in
ALP56.
4. Discussion
The pathogenesis of breast cancer metastasis con-
sists of a series of linked and selective steps including
tumor cell invasion, circulation, adhesion, and
growth in distant organs [5]. Invasiveness, one of
the initial steps in metastasis, requires the expression
of degradative enzymes, such as plasminogen activa-
tor [59], collagenase [18], and cathepsins [60]. We
identi¢ed a novel gene, ALP56, from the highly tu-
morigenic and metastatic breast cancer cell line
MDA-MB-435. Comparison of the open reading
frame showed its homology to members of the pepsin
family of aspartic proteases.
Aspartic proteases have been implicated in malig-
nant breast cancer growth by acting on basement
membranes and by releasing matrix-bound growth
factors [61]. In addition, it has been shown that the
propeptide of the aspartic protease cathepsin D has
mitogenic activity on breast cancer cells [62].
Although the biological function of ALP56 in tumor
progression remains to be examined, one hypothesis
is that this novel aspartic protease might play a sim-
ilar role as cathepsin D in tumor growth and meta-
stasis. The expression level of cathepsin D was shown
to be higher in malignant tumors compared to be-
nign lesions [63]. Similarly, we found ALP56 expres-
sion elevated in highly invasive breast cancer cell
lines. The expression of ALP56 in primary tumors
and lung metastasis of mice injected with MDA-
MB-435 suggests that this gene is associated with
tumor growth and metastasis. Furthermore, elevated
levels of ALP56 transcripts were found in primary
breast and colon tumors, as well as in liver metastasis
of patient samples. The ¢nding that ALP56 is not
overexpressed in prostate cancer compared to normal
prostate tissues suggests involvement of this protease
in only certain cancers. Although these data associate
ALP56 with human cancer, a role for ALP56 as
prognostic marker and as putative therapeutic target
remains to be de¢ned.
ALP56 shows homology to members of the pepsin
family of aspartic proteases. The pepsin family in-
cludes enzymes from the digestive tract, such as pep-
sinogen and lysosomal enzymes, like cathepsin D.
Other aspartic enzymes in this class are involved
post-translational processing, such as renin [53] and
the less related retroviral proteases [64]. Members of
this heterogeneous group of proteases di¡er in their
tissue distribution, cellular locations, pH require-
ments for activation [65], as well as in their substrate
speci¢cities [53]. For example, pepsinogens are pre-
dominantly expressed in the epithelial cells of the
stomach mucosa and localized in secretory granules,
whereas cathepsin D is expressed in all mammalian
tissues and is localized in lysosomes of normal cells
except erythrocytes [66]. Similarly, ALP56 transcripts
were detected in a large number of human tissues
except brain and peripheral blood lymphocytes.
The highest expression of ALP56 was detected in
pancreas, prostate and placenta. It is interesting to
notice that expression of a new member of this fam-
ily, napsin, was detected in human lung adenocarci-
noma [67].
Aspartic proteases are mostly expressed as inactive
precursor proteins, which have to undergo autocata-
lytic processing for activity [52,68]. Common to all
aspartic proteases, ALP56 contains a functional sig-
nal sequence as demonstrated by in vitro protection
assays with microsomes (Fig. 7). ALP56 also shares
sequence homology in the propeptide region with
other members of the pepsinogen family. We rea-
soned that ALP56 exists as an inactive precursor
and must likewise undergo a similar activation pro-
cess. Transient transfection experiment of COS cells
demonstrated that ALP56 cDNA encodes a 60-kDa
protein. In addition to this 60-kDa protein, we con-
sistently observed two minor bands at approximately
14 and 17 kDa from C-terminus. The absence of
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these C-terminal polypeptides in a mutant version of
ALP56, in which both aspartic acid residues in the
catalytic centers have been mutated to alanine resi-
dues, suggests these peptides are a consequence of
the catalytic activity of ALP56. This may be the re-
sult of autocatalytic activity or ALP56 may be in-
volved in a proteolytic cascade which results in its
own cleavage. It is possible, however, that introduced
changes in the protein structure may prevent inter-
actions with an endogenous protease. The presence
of a hydrophobic stretch of amino acids near the C-
terminus of the protein corresponding with the size
of the protected ALP56 by microsomes suggests that
ALP56 is an integral membrane protease. There is a
fast growing list of integral membrane proteases in-
volved in cell invasion which may act in a large com-
plex. It is then conceivable that ALP56 may contrib-
ute to a complex proteolytic cascade in neoplastic
cells which is necessary for metastasis. It will be of
interest to characterize this novel protease in order to
identify substrates for ALP56 and to shed light not
only on its normal function, but also on its putative
role in tumor growth and metastasis.
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